Author: Ravi Shankar

Key Takeaways:

• Parsons introduced iNET® Convergent Response, a solution that unifies capabilities of two Parsons’ products by combining the power of iNET® and Team Awareness Kit (TAK) into a unified operational platform.
• iNET® Convergent Response enables faster coordination and decision-making across transportation, emergency management, public safety, and critical infrastructure operations.
• iNET® Convergent Response extends Parsons’ dual-use technology portfolio by connecting real-time situational awareness with operational execution.

CHANTILLY, Va., Nov. 10, 2026 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) announced today the launch of iNET® Convergent Response, a new solution package that combines the company’s Intelligent Networks® (iNET®) platform with Team Awareness Kit (TAK) capabilities. The solution delivers enhanced situational awareness, operational coordination, and decision support across national security, transportation, public safety, critical infrastructure, and emergency management markets.

By integrating TAK’s real-time information sharing with iNET®’s orchestration, workflow automation, and operational execution capabilities, iNET® Convergent Response helps organizations move from detection to coordinated action plans more efficiently. The platform connects personnel, infrastructure, and agencies across jurisdictions to support informed decision-making during planned events, emergencies, and security incidents.

“Whether supporting critical infrastructure, securing major public events, or responding to emergencies, organizations need the ability to turn information into action at speed,” said Rico Lorenzo, Chief Technology Officer, Parsons. “iNET® Convergent Response brings together trusted situational awareness and operational execution from our Federal and Critical Infrastructure segments in a single platform, enabling customers to coordinate resources more effectively, strengthen security, and respond with greater confidence in mission-critical environments.”

For decades, Parsons has helped communities worldwide move smarter with its iNET® Smart Mobility Platform. Cities, states, and municipalities rely on iNET® to improve mobility, safety, and operational performance across transportation networks of all sizes. Advanced operational capabilities, artificial intelligence, and machine learning help agencies identify issues, develop response strategies, and coordinate solutions in real time.

TAK is a scalable information-sharing platform that strengthens operational awareness and emergency response across military, federal, public safety, and civilian operations. Integrated with iNET®, it turns real-time field observations into unified responses across customer missions. Together, these capabilities support faster evacuations, smarter routing, improved crowd management, stronger disaster response, critical infrastructure protection, and enhanced force protection while improving collaboration and visibility among federal, state, and local agencies during daily operations, special events, and large-scale incidents.

The solution builds on Parsons’ experience delivering dual-use technologies. By incorporating TAK’s proven capabilities into iNET®, Parsons advances technologies that improve operational performance, strengthen resilience, and help organizations execute critical missions with greater speed, coordination, safety, and confidence.

For decades, Parsons has delivered leading solutions and capabilities to global events, bringing its unique positioning and experience to provide the necessary expertise, innovative solutions, and integrated security and critical infrastructure solutions for the successful execution of large-scale events and national gatherings. The company has provided integrated security and critical infrastructure solutions to past Olympics, World Cups, Expos, and the Super Bowl, including its iNET® and TAK solutions. The company’s 80-plus-year history in infrastructure design and engineering coupled with 40 years of cutting-edge cybersecurity and physical security expertise, help ensure Parsons’ ability to safeguard national assets, protect communities, and enhance global security.

To learn more about Parsons’ operational coordination and response solutions, visit https://www.parsons.com/products/inet-convergent-response/.

EXIM Approved: 2652

About Parsons:
Parsons (NYSE: PSN) is a leading disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and electronic warfare, space and missile defense, transportation, water and environment, urban development, and critical infrastructure protection. Please visit Parsons.com and follow us on LinkedIn to learn how we’re making an impact.

Media Contact:     
Bernadette Miller
+1 980.253.9781
bernadette.miller@parsons.com

Investor Relations Contact:
Dave Spille
+1 703.775.6191
Dave.Spille@parsons.us

• Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing
• S-4 Declared Effective by SEC; Stockholder Vote Scheduled for December 9, 2026

BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), today provided a business update and reported financial results for the third quarter ended September 30, 2026.

The Company continues to advance its proposed merger (the “Merger”) with Avere Therapeutics, Inc., a privately held biotechnology company focused on oral therapies for IL-23-driven inflammatory diseases (“Avere”), which is now supported by approximately $820 million of committed financing from a syndicate of leading healthcare-focused and institutional investors. The financing is expected to provide substantial capital to support development of Avere’s lead program, AVR-001, other corporate purposes and the future operations of the combined company following completion of the proposed transaction.

“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics,” said Michael Richman, President and CEO of NextCure. “Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere’s clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”

Recent Business Highlights

Proposed Merger with Avere

• Financing commitments supporting the Merger increased to approximately $820 million, consisting of the previously announced $320 million concurrent private placement and an additional $500 million private placement, of which approximately $266 million will be satisfied through the contribution and cancellation of Avere’s outstanding convertible notes.
• The financing is supported by a syndicate of leading healthcare-focused and institutional investors and is expected to provide substantial capital to advance development of AVR-001 and support future operations of the combined company.
• Subject to stockholder approval and other customary closing conditions, the combined company is expected to operate as Avere and trade on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol “AVRX.”
• On November 2, 2026, the Delaware Court of Chancery entered a final order validating the Company’s July 2025 reverse stock split amendment and all shares issued in reliance thereon.
• On November 6, 2026, the Registration Statement on Form S-4 relating to the proposed merger was declared effective by the Securities and Exchange Commission (“SEC”). The Company established November 3, 2026 as the record date and scheduled a special meeting of stockholders for December 9, 2026 at 9:00 a.m. Eastern Time to consider and vote upon the proposals necessary to complete the merger.
• Existing NextCure stockholders are expected to retain an ownership interest in the combined company and receive contingent value rights (“CVRs”) tied to specified legacy NextCure assets.

LNCB74 Transition and Corporate Restructuring

• In August 2026, NextCure and LigaChem Biosciences, Inc. (“LigaChem”) entered into a Transition and Continuation Agreement pursuant to which LigaChem elected to become the sole developing party for the LNCB74 program (“LNCB74”) and assumed responsibility for all program costs incurred on or after July 1, 2026, with NextCure providing transition support reimbursed by LigaChem.
• On October 6, 2026, the parties completed the transfer of the LNCB74 investigational new drug application (IND) and related regulatory responsibilities to LigaChem.
• NextCure remains eligible to receive future development, regulatory and commercial milestone payments, as well as royalties on potential future net sales of LNCB74. Subject to the terms of the proposed contingent value rights arrangement, these economic interests are expected to be included in the legacy assets supporting the CVRs to be issued to pre-Merger NextCure stockholders.
• During the third quarter, the Company completed significant restructuring initiatives, including workforce reductions, termination of facility leases and disposition of all laboratory, manufacturing and facility-related assets, resulting in substantial reduction to the Company’s future operating cash requirements.

Strategic Alternatives for Legacy Assets

• The Company completed treatment and transition activities for patients enrolled in the SIM0505 clinical study by August 31, 2026 and continues to evaluate opportunities to partner, license or otherwise monetize rights associated with the program.
• The Company continues to evaluate strategic alternatives to derive value from its legacy asset portfolio for stockholders, including potential licensing, partnering and other opportunities.

Financial Results for the Quarter Ended September 30, 2026

• Cash, cash equivalents, and marketable securities as of September 30, 2026 were $8.7 million, compared to $41.8 million as of December 31, 2025. The decrease of $33.1 million was primarily attributable to cash used to fund operations of $35.2 million, partially offset by $1.2 million of net proceeds from equity sales under the Company’s existing at-the-market (ATM) program and $0.7 million from the sale of fixed assets.
• Research and development expenses were $4.5 million for the three months ended September 30, 2026, compared to $6.1 million for the three months ended September 30, 2025. The decrease of $1.6 million was primarily attributable to lower personnel costs resulting from the Company’s restructuring initiatives, lower laboratory services and supplies costs and lower depreciation expense following the disposition of all the Company’s fixed assets.
• General and administrative expenses were $4.4 million for the three months ended September 30, 2026, compared to $2.8 million for the three months ended September 30, 2025. The increase of $1.6 million was primarily attributable to $1.8 million of higher legal and professional fees incurred in connection with the Merger.
• Restructuring and asset impairment charges, net were ($2.0) million for the three months ended September 30, 2026 and included a gain of $3.4 million on the termination of our leases and a gain of $0.4 million on the sale of fixed assets, partially offset by severance charges of $1.8 million associated with our restructuring initiatives.
• Net loss was $6.8 million for the three months ended September 30, 2026, compared to a net loss of $8.6 million for the three months ended September 30, 2025. The improvement was primarily driven by the lower research and development expenses mentioned above and $2.0 million of gains, net associated with the Company’s restructuring activities, partially offset by the higher general and administrative expenses mentioned above.

About the Merger

On July 14, 2026, NextCure announced a definitive merger agreement with Avere.

On November 2, 2026, the Delaware Court of Chancery entered a final order validating the Company’s July 2025 reverse stock split amendment and all shares issued in reliance thereon.

On November 6, 2026, the Registration Statement on Form S-4 relating to the proposed merger was declared effective by the SEC. NextCure commenced distribution of definitive proxy materials and established November 3, 2026 as the record date for the special meeting of stockholders scheduled for December 9, 2026 at 9:00 a.m. Eastern Time.

Since announcement of the transaction, total financing commitments supporting the Merger have increased to approximately $820 million, consisting of the previously announced $320 million concurrent private placement and an additional $500 million private placement, of which approximately $266 million will be satisfied through the contribution and cancellation of Avere’s outstanding convertible notes. The financing is expected to provide substantial capital to support development of AVR-001 and the future operations of the combined company.

Assuming the Merger is completed, the combined company is expected to operate as Avere and trade on the Nasdaq under the ticker symbol “AVRX.” Existing NextCure stockholders are expected to receive contingent value rights related to specified legacy NextCure assets and retain a minority ownership interest in the combined company.

Completion of the Merger remains subject to stockholder approval and other customary closing conditions. NextCure has set a special stockholder meeting date of December 9, 2026 to vote on approval of the various Merger-related items.

About NextCure, Inc.

NextCure is a biopharmaceutical company focused on managing its legacy clinical and intellectual property assets, pursuing opportunities to maximize those legacy assets, fulfilling ongoing obligations under its existing collaboration and licensing agreements and advancing completion of the Merger with Avere.

Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning NextCure, Avere, the Merger and other matters, including with respect to the structure, timing and completion of the Merger; the combined company’s listing on Nasdaq after closing of the Merger; expectations regarding the ownership structure of the combined company; expectations regarding the contingent value rights; the future operations of the combined company; the nature, strategy and focus of the combined company; as well as funding for our operations, our expected cash runway, objectives and expectations for our business, operations and financial performance and condition, and opportunities to monetize, partner, license or otherwise derive value from our legacy assets. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “should”, “due”, “estimate”, “expect”, “intend”, “hope”, “may”, “objective”, “plan”, “predict”, “project”, “potential”, “positioned”, “seek”, “target”, “towards”, “forward”, “later”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.

Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: risks associated with the possible failure to satisfy the conditions to the closing or consummation of the Merger, including NextCure’s failure to obtain stockholder approval for the Merger; risks associated with the potential failure to complete the financing transaction in a timely manner or at all; risks associated with the uncertainty as to the timing of the consummation of the Merger and the ability of each of NextCure and Avere to consummate the transactions contemplated by the Merger; risks associated with NextCure’s continued listing on The Nasdaq Stock Market, LLC until closing of the Merger; the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger prior to the closing or consummation of the Merger; risks associated with the possible failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results; the effect of the completion of the Merger on the combined company’s business relationships, operating results and business generally; risks associated with the combined company’s ability to manage expenses and unanticipated spending and costs that could reduce the combined company’s cash resources; risks related to the combined company’s ability to correctly estimate its operating expenses and other events; changes in capital resource requirements; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs; the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger or the transactions contemplated thereby; the ability of the combined company to obtain, maintain and protect its intellectual property rights, in particular those related to its product candidates; the combined company’s ability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials; the combined company’s ability to replicate in later clinical trials positive results found in preclinical studies and clinical trials of its product candidates; the combined company’s ability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations; regulatory requirements or developments and the combined company’s ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities; changes to clinical trial designs and regulatory pathways; competitive responses to the Merger and changes in expected or existing competition; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; risks regarding our ability to monetize, partner, license or otherwise realize value from our legacy development programs and assets and other intellectual property; our expenses, future revenues, capital requirements, needs for or ability to obtain additional financing and the period over which our current cash and cash equivalents will be sufficient to fund our operations; market and other conditions; the timing and success of strategic transactions involving our legacy programs and our ability to receive future milestone, royalty or other contingent payments under our existing collaboration and licensing arrangements; the potential benefits of and our ability to maintain our relationship with LigaChem, Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.), and other third-party vendors and collaborators; our ability to retain key personnel; changes in international relations, tariffs, and other trade regulations between the U.S. and China; developments and projections relating to our competitors and our industry, including competing therapies; and the impact of current and future laws and regulations.

More detailed information on these and additional factors that could affect NextCure’s actual results are described under the heading “Risk Factors” in NextCure’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q and in NextCure’s other filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

No Offer or Solicitation

This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy, or a solicitation of any vote, consent or approval in any jurisdiction in connection with the Merger or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Important Additional Information About the Merger Will Be Filed with the SEC

In connection with the proposed Merger, NextCure filed with the SEC a registration statement on Form S-4 containing a proxy statement/prospectus relating to the proposed Merger. On November 6, 2026, the registration statement on Form S-4 was declared effective by the SEC, and NextCure commenced distribution of the definitive proxy statement/prospectus to its stockholders. NextCure and Avere may also file other documents with the SEC regarding the proposed Merger. This communication is not a substitute for the registration statement, the proxy statement/prospectus or any other document that NextCure may file with the SEC in connection with the Merger.

INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT NEXTCURE, AVERE, THE MERGER AND RELATED MATTERS.

Investors and security holders may obtain free copies of the registration statement, the proxy statement/prospectus and other documents filed with the SEC by NextCure through the website maintained by the SEC at www.sec.gov or from NextCure’s website at www.nextcure.com under the “Investors” section.

Participants in the Solicitation

NextCure, Avere and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NextCure’s stockholders in respect of the Merger. Information regarding the directors and executive officers of NextCure is contained in NextCure’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC, and in subsequent filings made by NextCure with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the Merger, and a description of their direct and indirect interests in the Merger, by security holdings or otherwise, will be included in the proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available. These documents may be obtained free of charge from the sources indicated above.

NextCure, Inc.
Selected Financial Information
Selected Statement of Operations Items:	Three Months Ended								Nine Months Ended
	September 30,								September 30,
(in thousands, except share and per share amounts)	2026				2025				2026				2025
Operating expenses:
Research and development	$	4,535			$	6,136			$	18,794			$	38,123
General and administrative		4,428				2,809				10,291				9,736
Restructuring and asset impairment charges, net		(2,044	)			–				3,033				–
Loss from operations		(6,919	)			(8,945	)			(32,118	)			(47,859	)
Other income, net		73				321				584				1,451
Net loss	$	(6,846	)		$	(8,624	)		$	(31,534	)		$	(46,408	)
Net loss per common share – basic and diluted	$	(1.29	)		$	(3.22	)		$	(5.97	)		$	(18.84	)
Weighted-average shares outstanding – basic and diluted		5,309,754				2,676,116				5,286,453				2,462,821
Selected Balance Sheet Items:
										September 30,				December 31,
(in thousands)										2026				2025
Cash, cash equivalents, and marketable securities									$	8,728			$	41,818
Total assets									$	9,700			$	50,183
Accounts payable and accrued liabilities									$	4,197			$	10,566
Total stockholders’ equity									$	5,503			$	34,943

Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com

Mike Moyer
Managing Director,
LifeSci Advisors, LLC
Phone: (617) 308-4306
mmoyer@lifesciadvisors.com

Revenue increased 42% sequentially as e-commerce and subscriptions expanded; 

Gross profit reached a record $796,000

SURPRISE, Ariz., Nov. 10, 2026 (GLOBE NEWSWIRE) — SenesTech, Inc. (NASDAQ: SNES), an innovator in rodent control, today announced financial results for the third quarter ended September 30, 2026.

Q3 2026 Financial Highlights

• Total revenue increased 42% sequentially to a record $1.097 million in Q3 2026, compared to $770,000 in Q2 2026, and increased 59% compared to $690,000 in Q3 2025. This was the second consecutive quarterly revenue record and the first quarter above $1 million, consistent with the preliminary revenue of approximately $1.1 million announced on October 15, 2026.
• E-commerce revenue increased 52% sequentially and 337% year over year, representing approximately 71% of total Q3 revenue.
• Subscription revenue increased 53% sequentially and 234% year over year. Combined subscribers across Amazon and the Company’s website increased 72% compared to Q2 2026, strengthening the recurring revenue base.
• Direct B2B revenue increased 19% sequentially and 2% year over year. Sequential growth was driven by process changes to the Company’s B2B efforts, which drove growth in the pest management, government and commercial verticals.
• Evolve® revenue increased 67% year over year to $979,000 and represented 89% of product revenue. ContraPest® revenue increased 13% year over year to $118,000, driven by higher refill sales.
• Gross profit increased 40% to a record $796,000 in Q3 2026, compared to $567,000 in Q2 2026, and increased 84% compared to $433,000 in Q3 2025.
• Gross margin was 72.6% in Q3 2026, compared to 73.6% in Q2 2026 and 62.8% in Q3 2025.
• Net loss for Q3 2026 was $2.0 million, compared to $1.8 million in Q2 2026 and $1.3 million in Q3 2025.
• Adjusted EBITDA loss was $1.4 million in Q3 2026, compared to $1.4 million in Q2 2026 and $1.1 million in Q3 2025.
• Cash and cash equivalents at the end of the quarter were $4.0 million. Subsequent to the end of the quarter, the Company raised $1.2 million in gross proceeds from the ATM.
• Net cash used in operating activities declined each quarter in 2026, falling to $1.3 million in Q3 from $1.7 million in Q2 2026 and $1.9 million in Q1 2026.

Recent Operational and Strategic Highlights

• Amazon Revenue and Subscriptions Continue to Grow: Amazon revenue increased each month of Q3, bringing in new customers and expanding the recurring subscription base.
• B2B Sales Team Expanded: The Company added two salespeople, bringing the team under Executive Vice President of Sales Jack Karabees to four, with two additional hires expected by year end. The team is focused on building repeat business across targeted domestic verticals.
• E-commerce Reach Expanded Through Grove Collaborative: SenesTech added Grove Collaborative as a third-party e-commerce channel, bringing Evolve® to an engaged base of consumers focused on sustainability.
• Assessment and Monitoring Services Launched for B2B Customers: In July, SenesTech began offering assessment services to help B2B customers measure rodent activity and understand the scope of an infestation. Customers can choose an assessment performed by SenesTech or deploy the Company’s tracking products themselves, with results analyzed using SenesTech’s internally developed AI tool. These services complement existing implementation and deployment services and are expected to provide an additional revenue opportunity.
• Municipal Results Support Broader Adoption: Chicago’s Wicker Park Bucktown program, which incorporated SenesTech’s assessment services and Evolve® into an integrated pest management approach, reduced average rat activity intensity by 88% over 12 months. Evolve has expanded to six Chicago-area Special Service Areas and wards. In Swampscott, Massachusetts, Evolve Rat, combined with sanitation and waste management improvements, helped reduce measured rodent activity by 43% over six months.
• Sandstrom Partners Engaged to Support Branding and Marketing: SenesTech engaged Sandstrom Partners, a Portland, Oregon, brand development firm whose clients have included Nike, Target and Coca-Cola, as a strategic advisor on marketing and branding. An early priority is helping retain Amazon customers and attract new customers by more clearly communicating how the Company’s rodent birth control products work.

Management Commentary

“SenesTech delivered a milestone third quarter, exceeding $1 million in quarterly revenue for the first time and setting new records for revenue, gross profit and subscription customers,” said Michael Edell, President and Chief Executive Officer of SenesTech. “These results demonstrate the momentum we are building. With e-commerce delivering strong growth and our expanded B2B sales team pursuing new opportunities, we are excited about the foundation we are establishing for continued growth.

“Our e-commerce business continues to lead the way, with revenue increasing 52% sequentially, driven by another record quarter on Amazon. Across Amazon and our website, combined subscription customers increased 72% sequentially, while subscription revenue grew 53%. We are reaching more customers and building ongoing relationships that support repeat purchases, greater revenue visibility and long-term customer value.

“We see direct B2B as the next significant driver of growth alongside our expanding e-commerce business. By expanding the sales team, we have increased our capacity to pursue opportunities across our targeted verticals. Direct B2B revenue increased 19% sequentially, and we believe our growing brand awareness, broader customer adoption and focused sales efforts position us to build on that progress,” Mr. Edell concluded.

“Record gross profit of $796,000 and a gross margin of 72.6% highlight the strength of our business model as revenue scales,” said Tom Chesterman, Chief Financial Officer of SenesTech. “Our focus is on translating this commercial momentum into sustained financial progress. We are also putting our cash to work more efficiently: excluding non-cash items such as stock-based and other non-cash compensation, depreciation and straight-line rent, sales and marketing has grown as a share of operating expenses compared to the third quarter of 2025, while general and administrative spending has declined as a share.”

Use of Non-GAAP Measures

Adjusted EBITDA is a non-GAAP measure and is not intended to be a substitute for those financial measures reported in accordance with GAAP. This measure has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to operating performance and liquidity trends. We use these non-GAAP financial measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. These adjustments may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of the non-GAAP measures to the nearest GAAP measure.

Conference Call Details

Date: Tuesday, November 10, 2026.

Time: 5 p.m. ET.

Call-in Information: Interested parties can access the live teleconference by dialing 1-844-308-3351 or 1-412-317-5407.

Webcast: https://app.webinar.net/EM53kOPaJDx

Webcast Replay: Available for 90 days on the Company’s website.

About SenesTech

SenesTech is the leader in rodent birth control and sustainable rodent population management, with a mission to support a healthier environment through the responsible management of animal pest populations. The Company’s Evolve® and ContraPest® fertility control solutions, along with its assessment and monitoring services, target reproduction to help reduce rodent populations. SenesTech serves consumer and professional markets with proven approaches that can be used independently or as part of an integrated pest management (IPM) program.

For more information, visit https://senestech.com/.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, without limitation, statements regarding expected growth in e-commerce, subscription and direct B2B revenue; the planned addition of two salespeople by year end; the anticipated benefits of the Company’s third-party e-commerce relationship with Grove Collaborative; the expansion of municipal adoption of Evolve®; the anticipated benefits of, and revenue opportunity from, the Company’s assessment services; the anticipated benefits of the Company’s engagement of Sandstrom Partners, including improved customer retention and acquisition; and the Company’s ability to use cash more efficiently.

Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as “believe,” “may,” “future,” “plan,” “will,” “should,” “expect,” “anticipate,” “eventually,” “project,” “estimate,” “continuing,” “intend” and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the Company’s ability to sustain revenue growth across its e-commerce and B2B channels; its reliance on Amazon and other third-party platforms; its ability to retain and grow subscribers; the ability of its sales team to generate direct B2B revenue; the continued adoption of its products by municipalities; market acceptance of its assessment services and its ability to deliver them profitably; the effectiveness of its marketing and branding initiatives; the Company’s history of losses and need for additional capital to fund operations; its ability to manage operating expenses and cash; competition; regulatory developments affecting its products, including EPA and state registration requirements; supply chain and manufacturing risks; general economic conditions; and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:

Investors: Robert Blum, Lytham Partners, LLC, (602) 889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., (928) 779-4143

SENESTECH, INC. BALANCE SHEETS (In thousands, except share and per share data) (Unaudited)
	September 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	3,951			$	7,575
Short-term investments		—				994
Accounts receivable, net		247				201
Inventory		966				994
Prepaid expenses and other current assets		398				297
Total current assets		5,562				10,061
Right to use asset, operating lease		2,211				2,336
Property and equipment, net		334				410
Other noncurrent assets		36				36
Total assets	$	8,143			$	12,843
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	357			$	183
Accrued expenses		615				383
Current portion of operating lease liability		151				139
Current portion of notes payable		65				61
Deferred revenue		45				32
Total current liabilities		1,233				798
Operating lease liability, less current portion		2,217				2,332
Notes payable, less current portion		95				145
Total liabilities		3,545				3,275
Stockholders’ equity:
Common stock		5				5
Additional paid-in capital		152,924				152,043
Accumulated deficit		(148,331	)			(142,480	)
Total stockholders’ equity		4,598				9,568
Total liabilities and stockholders’ equity	$	8,143			$	12,843

SENESTECH, INC. STATEMENTS OF OPERATIONS (In thousands, except share and per share data) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Revenues, net	$	1,097			$	690			$	2,360			$	1,800
Cost of sales		301				257				659				645
Gross profit		796				433				1,701				1,155
Operating expenses:
Research and development		418				400				1,217				1,245
Sales and marketing		1,082				425				2,218				1,277
General and administrative		1,287				955				4,238				3,257
Total operating expenses		2,787				1,780				7,673				5,779
Loss from operations		(1,991	)			(1,347	)			(5,972	)			(4,624	)
Interest income, net		35				49				121				45
Net loss	$	(1,956	)		$	(1,298	)		$	(5,851	)		$	(4,579	)
Weighted average shares outstanding — basic and diluted		5,420,899				4,668,009				5,329,923				2,619,841
Loss per share — basic and diluted	$	(0.36	)		$	(0.28	)		$	(1.10	)		$	(1.75	)

SENESTECH, INC. STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Cash flows from operating activities:
Net loss	$	(1,956	)		$	(1,298	)		$	(5,851	)		$	(4,579	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		276				47				481				228
Depreciation and amortization		32				29				94				103
Other non-cash expenses, net		7				43				16				87
Changes in operating assets and liabilities, net		319				(200	)			300				75
Net cash used in operating activities		(1,322	)			(1,379	)			(4,960	)			(4,086	)
Cash flows from investing activities:
Purchase of held-to-maturity investments		—				(2,964	)			—				(2,964	)
Maturity of held-to-maturity investment		—				—				1,000				—
Purchase of property and equipment		(18	)			(42	)			(18	)			(125	)
Net cash provided by (used in) investing activities		(18	)			(3,006	)			982				(3,089	)
Cash flows from financing activities:
Proceeds from the exercise of warrants, net		—				5,622				—				10,482
Proceeds from issuances of common stock, net		227				—				400				2,706
Repayments of notes payable		(16	)			(14	)			(46	)			(42	)
Net cash provided by financing activities		211				5,608				354				13,146
Increase (decrease) in cash and cash equivalents		(1,129	)			1,223				(3,624	)			5,971
Cash and cash equivalents, beginning of period		5,080				6,055				7,575				1,307
Cash and cash equivalents, end of period	$	3,951			$	7,278			$	3,951			$	7,278

SENESTECH, INC. Itemized Reconciliation Between Net Loss and Adjusted EBITDA (non-GAAP) (In thousands) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Net loss (as reported, GAAP)	$	(1,956	)		$	(1,298	)		$	(5,851	)		$	(4,579	)
Non-GAAP adjustments:
Stock-based and non-cash compensation		524				18				757				299
Severance costs		—				—				503				27
One-time legal costs		—				111				217				356
Interest income, net		(35	)			(49	)			(121	)			(45	)
Depreciation expense		32				29				94				103
Non-cash operating lease expense		7				49				22				87
Total non-GAAP adjustments		528				158				1,472				827
Adjusted EBITDA loss (non-GAAP)	$	(1,428	)		$	(1,140	)		$	(4,379	)		$	(3,752	)

BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) — Factorial Energy Inc. (“Factorial”) (Nasdaq: FAC), a global leader in solid-state battery technology, today announced financial and business results for the third quarter ended September 30, 2026.

The Company has issued a shareholder letter discussing its third quarter 2026 financial and business results and recent milestones. Factorial recorded its first commercial revenue, well ahead of its previously disclosed 2027 objective, and its aerospace program cells achieved the 450 Wh/kg target set for year end. The shareholder letter may be accessed on the Investors section of Factorial’s website at https://ir.factorialenergy.com/.

Factorial will host a conference call today at 4:30 PM ET to discuss the Company’s financial results. The live webcast of the conference call can be accessed through the Investors section of Factorial’s website. For those unable to access the webcast, the conference call can be accessed by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international). To access the replay of the call, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and enter pass code 13763249.

About Factorial Energy

Factorial Energy (Nasdaq: FAC) is a leading American solid-state battery innovator backed by IQT – the not-for-profit strategic investor for the U.S. national security community and America’s allies – and Mercedes-Benz, Stellantis, Hyundai, and Kia. Through its proprietary FEST® and Solstice™ platforms, engineered for scalable manufacturing, Factorial delivers industry-leading performance across aerospace, energy storage and mobility applications. Factorial’s technology powered a Group I drone to a world record for flight duration in 2026, flying 521 minutes and roughly 483 km (300 miles) in a single mission. In automotive, a lightly modified Mercedes-Benz test vehicle surpassed 1,200 km of range on a single charge in real-world testing, and the technology was also integrated into a fully built Dodge Charger Daytona demonstration vehicle with Stellantis in 2026. For more information, visit www.factorialenergy.com.

Forward-Looking Statements

Certain statements in this communication may be considered forward-looking statements. Forward-looking statements generally relate to future events or Factorial’s future financial or operating performance, including expectations regarding manufacturing capabilities, commercialization plans, business strategy, customer programs, partnerships, supply-chain development and production readiness. In some cases, forward-looking statements can be identified by terms such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “anticipate,” “believe,” “predict,” “project,” “target,” “plan,” “potentially” or similar terminology. These statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied. For a discussion of factors that could cause actual results to differ materially, see “Risk Factors” in Factorial’s filings with the Securities and Exchange Commission. Factorial undertakes no obligation to update forward-looking statements except as required by law.

Factorial has used, and intends to continue to use, its Investor Relations website (https://ir.factorialenergy.com), as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Information on or that can be accessed through Factorial’s Investor Relations website, or that is contained in any website to which a hyperlink is provided herein is not part of this press release, and the inclusion of Factorial’s Investor Relations website address, and any hyperlinks are only inactive textual references.

Factorial IR Contact: IR@factorialenergy.com
Factorial Media Contact: Factorial@antennagroup.com

Achieves 99.5% Median Two-Qubit Fidelity on 108-Qubit System, Further Validating Chiplet-Based QPU Architecture

BERKELEY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced financial results for the third quarter ended September 30, 2026 and provided an update on recent business and technology milestones.

Third Quarter 2026 Financial Highlights

• Total revenues for the three months ended September 30, 2026 were $1.4 million.
• Total revenues for the nine months ended September 30, 2026 were $10.9 million, compared with $5.2 million for the first nine months of 2025, representing growth of approximately 110%.
• Operating loss for the three months ended September 30, 2026 was $33.2 million.
• For the three months ended September 30, 2026, GAAP net loss was $3.1 million and non-GAAP net loss was $20.5 million.
• For the three months ended September 30, 2026, GAAP diluted net loss per share was $0.08 and non-GAAP diluted net loss per share was $0.06.
• As of September 30, 2026, cash, cash equivalents and available-for-sale investments totaled $497.1 million. The Company had no debt.
• Full-year outlook: 2026 revenue expected to be approximately $20 million, up significantly from 2025, assuming C-DAC customer acceptance and associated revenue recognition in the fourth quarter.

Management Commentary

“Rigetti delivered meaningful progress during the third quarter across system performance, technology development and strategic execution,” said Dr. Subodh Kulkarni, Rigetti CEO. “Our Cepheus-1-108Q system achieved our goal of 99.5% median two-qubit gate fidelity, demonstrating continued performance improvement at the 100-plus-qubit level and further validating our chiplet-based approach to scaling superconducting quantum computers.

“We also signed a definitive $100 million agreement with the U.S. Department of Commerce,” Dr. Kulkarni continued. “Building on the progress achieved this quarter, our next major system objective is to demonstrate a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028.”

Rigetti ended the third quarter of 2026 with a strong cash position and no debt, providing flexibility to continue investing in its technology roadmap and customer opportunities.

Business, Strategic and Technology Updates

Technology Performance and Roadmap

• Rigetti’s superconducting systems continuously achieve gate speeds of 50-70 nanoseconds, which is about 10,000 times faster than trapped-ion systems and 100 times faster than neutral-atom systems.
• Cepheus-1-108Q achieved 99.5% median two-qubit gate fidelity, meeting its performance milestone and further validating the Company’s chiplet architecture.
• Cepheus-1-108Q achieved 99.6% median two-qubit gate fidelity on an 80 qubit sublattice and 99.7% median two-qubit gate fidelity on a 50 qubit sublattice.
• Cepheus-1-108Q is based on 12 interconnected 9-qubit chiplets. The performance improvement reflects work across chip design, materials, fabrication, calibration and system engineering while preserving the Company’s modular architecture.
• Rigetti is targeting a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028. The system is expected to have a larger qubit count per chiplet, faster readout and expanded cryogenic capacity.
• Rigetti continues to target a path toward systems with approximately 1,000 qubits, approximately 99.9% two-qubit gate fidelity, and gate speeds below 50 nanoseconds within approximately three years. The Company believes this combination of scale, fidelity and speed could provide a platform for demonstrating quantum advantage.
• For the 1,000+ qubit system, Rigetti plans to increase the density of qubits in a single fridge as opposed to networking multiple fridges together. The Company believes this approach enables higher performance at a lower cost on the path toward building systems with thousands, and eventually tens of thousands, of qubits.
• In support of its roadmap, the Company has continued investing in dilution refrigeration capacity and related infrastructure that can support higher-qubit-count systems. Rigetti believes its chiplet-based and open modular architecture provides a practical framework for scaling over time.

Definitive Agreement with the U.S. Department of Commerce

• In September 2026, Rigetti signed a definitive agreement with the U.S. Department of Commerce for an award of up to $100 million under the CHIPS Research and Development Office Broad Agency Announcement pursuant to the CHIPS Act.
• The award supports three research and development programs focused on miniaturized readout electronics, expanded cryogenic capacity through a new cryostat architecture, and fabrication capabilities for high-connectivity chip architectures. As a condition of the award, the Department received a minority, non-controlling equity stake in Rigetti.

Conference Call and Webcast

Rigetti will host a conference call today, November 10, 2026, at 5:00 pm ET, or 2:00 pm PT, to discuss its third quarter 2026 financial results.

A live audio webcast of the conference call will be available at https://edge.media-server.com/mmc/p/83k45ubv or the “Events & Presentations” section of the Company’s Investor Relations website at https://investors.rigetti.com/. A replay of the conference call will be available at the same locations following the conclusion of the call for one year.

To participate in the live call, you must register using the following link: https://register-conf.media-server.com/register/BI3d578e1c33714315baae79132e216c8c. Once registered, you will receive dial-in numbers and a unique PIN. When you dial in, you will input your PIN and be routed into the call. If you register and forget your PIN, or lose the registration confirmation email, simply re-register to receive a new PIN.

About Rigetti

Rigetti is a pioneer in full-stack quantum computing. Rigetti quantum computers are based on superconducting qubits, which are widely believed to be the leading qubit modality given their maturity, clear path to scaling, and fast gate speeds. Rigetti quantum computing systems achieve gate speeds of 50-70 nanoseconds, which is about 10,000 times faster than trapped-ion systems and 100 times faster than neutral-atom systems.

Rigetti sells on-premises 9-qubit to 108-qubit quantum computing systems, which support national laboratories and quantum computing centers. Rigetti’s Cepheus 36-qubit to 108-qubit systems are based on the Company’s proprietary chiplet-based technology and include the Company’s control electronics. Rigetti’s 9-qubit Novera QPU supports a broader R&D community with a high-performance, on-premises QPU designed to plug into a customer’s existing cryogenic and control systems.

The Company operates quantum computers over the cloud through its Rigetti Quantum Cloud Services (QCS) platform, enabling global enterprise, government, and research clients to pursue R&D. The Company’s proprietary quantum-classical infrastructure provides high-performance integration with public and private clouds for practical quantum computing.

Rigetti developed the industry’s first multi-chip quantum processor for scalable quantum computing systems. Leveraging this proprietary technology, Rigetti deployed the industry’s largest multi-chip quantum computer in 2026 with Cepheus-1-108Q, based on twelve 9-qubit chiplets tiled together. The Company designs and manufactures its chips in-house at Fab-1, the industry’s first dedicated and integrated quantum device manufacturing facility. Learn more at https://www.rigetti.com/.     

Contacts

Rigetti Computing Investor Contact:
IR@Rigetti.com

Rigetti Computing Media Contact:
press@rigetti.com

Non-GAAP Financial Measures

To supplement Rigetti’s consolidated financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures: non-GAAP net loss, non-GAAP net loss per share attributable to common stockholders-basic and non-GAAP net loss per share attributable to common stockholders-diluted. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance. Non-GAAP net loss is defined as GAAP net loss excluding stock-based compensation expenses, change in fair value of derivative warrant liabilities and change in fair value of earn-out liabilities, non-GAAP net loss per share attributable to common stockholders-basic is defined as non-GAAP net loss divided by the weighted average shares used to compute net loss per share attributable to common stockholders-basic and non-GAAP net loss per share attributable to common stockholder-diluted is defined as non-GAAP net loss divided by the weighted average shares used to compute net loss per share attributable to common stockholders-diluted. The Company excludes stock-based compensation expenses, change in fair value of derivative warrant liabilities and change in fair value of earn-out liabilities from non-GAAP net loss, non-GAAP net loss per share attributable to common stockholders-basic and non-GAAP net loss per share attributable to common stockholders-diluted, primarily because these are non-cash items that the Company believes are not reflective of ongoing operating results and such items may not be comparable from period to period due to changes in the fair market value of the Company’s common stock, which is influenced by external factors such as the volatility of public markets and the performance of the Company’s peers. These non-GAAP financial measures, which are included in this press release and which may be referred to on the conference call discussing the Company’s third quarter financial results, are provided as supplemental information to the financial measures presented in this press release and discussed on the conference call that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. For a reconciliation of each non-GAAP financial measure to its most directly comparable GAAP measure, please refer to the reconciliation tables at the end of this press release.

Cautionary Language and Forward-Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the federal securities laws, including statements with respect to the Company’s expectations with respect to its future success and performance, including the target of a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028, with the expectation of having a larger qubit count per chiplet, faster readout, and expanded cryogenic capacity; the target of a system with approximately 1,000 qubits, approximately 99.9% two-qubit gate fidelity, and gate speeds below 50 nanoseconds within approximately three years; the belief that that combination of scale, fidelity, and speed of the system targeted within three years could provide a platform for demonstrating quantum advantage; the belief that achieving 99.5% median two-qubit fidelity on the 108-qubit system further validates the Company’s chiplet architecture; the plans to increase the density of qubits in a single fridge as opposed to networking multiple fridges together with the belief that this approach enables higher performance at a lower cost on the path towards building systems with thousands, and eventually tens of thousands, of qubits; the belief that a chiplet-based and open modular architecture provides a practical framework for scaling over time; and the Company’s expectation that full-year 2026 revenue will be approximately $20 million, including the expected customer acceptance of the C-DAC system and associated revenue recognition in the fourth quarter of 2026. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the Company’s ability to achieve milestones, technological advancements, including with respect to its technology roadmap; performance under the Other Transaction Agreement with the Department, the receipt of funding thereunder; the Company’s ability to deliver products to customers in time or at all, including actions by customers, such as controls over their facilities and cancelling orders; the timing of customer acceptance and revenue recognition for system sales, including with respect to the C-DAC system; the ability of the Company to obtain government contracts successfully and in a timely manner and the availability of government funding; the potential of quantum computing; the success of the Company’s partnerships and collaborations; the Company’s ability to accelerate its development of multiple generations of quantum processors; the outcome of any legal proceedings that may be instituted against the Company or others; the ability to maintain relationships with customers and suppliers and attract and retain management and key employees; costs related to operating as a public company; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business, or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and expansion plans; the expected use of proceeds from the Company’s past and future financings or other capital; the sufficiency of the Company’s cash resources; unfavorable conditions in the Company’s industry, the global economy or global supply chain, including rising inflation and interest rates, deteriorating international trade relations, political turmoil, natural catastrophes, warfare, and terrorist attacks; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and other documents filed by the Company from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements other than as required by applicable law. The Company does not give any assurance that it will achieve its expectations.

RIGETTI COMPUTING, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except number of shares and par value)
		September 30,				December 31,
		2026				2025
		(unaudited)
Assets
Current assets:
Cash and cash equivalents		$	45,799			$	44,851
Available-for-sale investments – short-term			337,514				398,660
Accounts receivable			3,891				2,551
Prepaid expenses			4,714				3,186
Other current assets			14,706				5,512
Total current assets			406,624				454,760
Available-for-sale investments – long-term			113,830				146,321
Property and equipment, net			87,476				57,051
Operating lease right-of-use assets			6,407				6,411
Other assets			9,607				2,031
Total assets		$	623,944			$	666,574
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	10,870			$	3,488
Accrued expenses and other current liabilities			6,876				5,582
Current derivative warrant liabilities			53,086				—
Current portion of deferred revenue			3,232				847
Current portion of operating lease liabilities			2,753				2,235
Total current liabilities			76,817				12,152
Deferred revenue, less current portion			698				698
Operating lease liabilities, less current portion			4,463				4,932
Derivative warrant liabilities			—				102,593
Total liabilities			81,978				120,375
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, none outstanding			—				—
Common stock, par value $0.0001 per share, 1,000,000,000 shares authorized, 342,704,604 shares issued and outstanding at September 30, 2026 and 331,282,895 shares issued and outstanding at December 31, 2025			34				33
Additional paid-in capital			1,337,893				1,316,126
Accumulated other comprehensive (loss) income			(2,370	)			997
Accumulated deficit			(793,591	)			(770,957	)
Total stockholders’ equity			541,966				546,199
Total liabilities and stockholders’ equity		$	623,944			$	666,574

RIGETTI COMPUTING, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026					2025			2026				2025
Revenue		$	1,411			$	1,947			$	10,949			$	5,220
Cost of revenue			554				1,543				6,526				3,808
Total gross profit			857				404				4,423				1,412
Operating expenses:
Research and development			25,495				15,020				66,180				43,997
Selling, general and administrative			8,548				5,933				25,442				19,478
Total operating expenses			34,043				20,953				91,622				63,475
Loss from operations			(33,186	)			(20,549	)			(87,199	)			(62,063	)
Other income (expense), net:
Interest income			4,758				5,598				15,179				10,792
Change in fair value of derivative warrant liabilities			25,291				(181,955	)			49,386				(149,250	)
Change in fair value of earn-out liabilities			—				(4,062	)			—				2,518
Total other income (expense), net			30,049				(180,419	)			64,565				(135,940	)
Net loss before provision for income taxes			(3,137	)			(200,968	)			(22,634	)			(198,003	)
Provision for income taxes			—				—				—				—
Net loss		$	(3,137	)		$	(200,968	)		$	(22,634	)		$	(198,003	)
Net loss available to common stockholders used in diluted loss per share		$	(28,428	)		$	(200,968	)		$	(72,020	)		$	(198,003	)
Net loss per share attributable to common stockholders – basic		$	(0.01	)		$	(0.62	)		$	(0.07	)		$	(0.65	)
Net loss per share attributable to common stockholders – diluted		$	(0.08	)		$	(0.62	)		$	(0.21	)		$	(0.65	)
Weighted average shares used to compute net loss per share attributable to common stockholders – basic			336,411				325,024				333,911				302,807
Weighted average shares used to compute net loss per share attributable to common stockholders – diluted			338,913				325,024				337,049				302,807

RIGETTI COMPUTING, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)
		Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities:
Net loss		$	(22,634	)		$	(198,003	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			9,231				5,797
Stock-based compensation			20,870				12,027
Change in fair value of earn-out liabilities			—				(2,518	)
Change in fair value of derivative warrant liabilities			(49,386	)			149,250
Accretion of available-for-sale securities			(2,145	)			(7,025	)
Non-cash lease expense			1,425				1,175
Changes in operating assets and liabilities:
Accounts receivable			(1,340	)			150
Prepaid expenses, other current assets and other assets			(10,425	)			(1,846	)
Deferred revenue			2,385				(113	)
Accounts payable			2,777				569
Accrued expenses and operating lease liabilities			181				(3,105	)
Net cash used in operating activities			(49,061	)			(43,642	)
Cash flows from investing activities:
Purchases of property and equipment			(42,598	)			(14,103	)
Purchases of available-for-sale securities			(229,329	)			(522,605	)
Maturities of available-for-sale securities			322,000				147,000
Net cash provided by (used in) investing activities			50,073				(389,708	)
Cash flows from financing activities:
Proceeds from sale of common stock through At-The-Market (ATM) Offerings			—				346,719
Proceeds from sale of common stock from Quanta private placement transaction			—				35,000
Payments of offering costs			(591	)			(888	)
Net proceeds from tax withholdings on sell-to-cover equity award transactions			—				6,272
Proceeds from issuance of common stock upon exercise of stock options			638				1,809
Proceeds from issuance of common stock upon exercise of warrants			138				3,000
Net cash provided by financing activities			185				391,912
Effects of exchange rate changes on cash and cash equivalents			(249	)			(103	)
Net Increase (decrease) in cash and cash equivalents			948				(41,541	)
Cash and cash equivalents – beginning of period			44,851				67,674
Cash and cash equivalents – end of period		$	45,799			$	26,133
Supplemental disclosures of other cash flow information:
Non-cash investing and financing activities:
Purchases of property and equipment recorded in accounts payable			6,721				1,586
Purchases of property and equipment recorded in accrued expenses			—				184
Prepayments for purchases of property and equipment recorded in other assets			(6,919	)			—
Non-cash addition to operating lease right-of-use asset and liability			1,421				—
Reclassification of earn-out liabilities to additional paid-in capital for vesting of Sponsor Vesting Shares			—				43,379
Reclassification of derivative liabilities to additional paid-in capital due to exercise of Public Warrants			121				1,609
Purchases of deferred offering costs in accounts payable			139				—
Unrealized (loss) gain on short term investments			(3,110	)			687

RIGETTI COMPUTING, INC. Reconciliation of Net Loss to Non-GAAP Net Loss and Calculation of Non-GAAP Net Loss per share attributable to common stockholders -basic and Non-GAAP Net Loss per share attributable to common stockholders-diluted (in thousands, except per share data) (unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Net loss (GAAP Measure)		$	(3,137	)		$	(200,968	)		$	(22,634	)			(198,003	)
Excluding:
Stock-based compensation expense			7,960				4,299				20,870				12,027
Change in fair value of derivative warrant liabilities			(25,291	)			181,955				(49,386	)			149,250
Change in fair value of earn-out liabilities			—				4,062				—				(2,518	)
Non-GAAP Net loss		$	(20,468	)		$	(10,652	)		$	(51,150	)		$	(39,244	)
Net loss per share attributable to common stockholders-basic (GAAP Measure)		$	(0.01	)		$	(0.62	)		$	(0.07	)		$	(0.65	)
Net loss per share attributable to common stockholders – diluted (GAAP Measure)		$	(0.08	)		$	(0.62	)		$	(0.21	)		$	(0.65	)
Non-GAAP Net loss per share attributable to common stockholders -basic		$	(0.06	)		$	(0.03	)		$	(0.15	)		$	(0.13	)
Non-GAAP Net loss per share attributable to common stockholders –diluted		$	(0.06	)		$	(0.03	)		$	(0.15	)		$	(0.13	)
Weighted average shares used to compute net loss per share attributable to common stockholders -basic			336,411				325,024				333,911				302,807
Weighted average shares used to compute net loss per share attributable to common stockholders -diluted			338,913				325,024				337,049				302,807

A majority-owned and controlled subsidiary of Fortress entered into an agreement with Cedars-Sinai to license FB-607, which is currently being evaluated in an ongoing Phase 2 study for IBS-D

MIAMI, Nov. 10, 2026 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that a majority-owned and controlled subsidiary of Fortress has entered into an exclusive licensing agreement with Cedars-Sinai to develop FB-607, a novel approach to potentially address the symptoms of irritable bowel syndrome with diarrhea (“IBS-D”).

FB-607 is a proprietary enteric-coated, pH-sensitive coformulation of rifaximin and N-acetylcysteine (“NAC”) and is designed to target the intestinal mucus layer and biofilms to improve outcomes for patients, including those who do not fully respond to rifaximin alone. The license agreement also enables the development of FB-607 for other indications, including hepatic encephalopathy.

Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “We are excited to develop FB-607 for the treatment of IBS-D and potentially provide a therapeutic option for patients that continue to have significant unmet need. IBS-D alone affects an estimated 4.5 million U.S. adults, and we believe there is a sizeable market for this opportunity, as these patients struggle with chronic symptoms and frequent relapses that can make their day-to-day life challenging.”

FB-607 is designed to potentially enhance clinical symptom relief and expand on the efficacy of monotherapy rifaximin, including in IBS-D patients with elevated hydrogen sulfide-producing bacteria, which have been associated with IBS-D. In a proof-of-concept study, the combination of rifaximin and NAC showed efficacy across several IBS-D endpoints including stool consistency, stool frequency, abdominal pain and bloating, as well as on breath testing. Additionally, in a toxin-induced rat model of IBS-D, rifaximin plus NAC normalized measured cytokine levels and reduced elevated levels of E. coli and Desulfovibrio.

FB-607 is currently being evaluated in a multi-center, randomized, double-blind, placebo-controlled Phase 2 study (NCT06727422) to assess the safety, efficacy and pharmacokinetics in the treatment of patients with IBS-D. The study is evaluating two dose levels of FB-607 against placebo, with 14 days of treatment and follow-up through week 14. The endpoints will assess improvement in abdominal pain and stool consistency during the four weeks after treatment and additional endpoints will assess stool frequency and overall response.

About FB-607
FB-607 is a proprietary enteric-coated, pH-sensitive coformulation of rifaximin and NAC. This novel formulation is designed to use NAC’s mucolytic properties to improve rifaximin’s access to bacteria within the intestinal mucus layer. While rifaximin is commonly used to treat IBS-D, symptom relapse is common in these patients and some patients may require repeat treatment as limited solubility and penetration into the intestinal mucus may reduce access to the bacteria within that layer for rifaximin alone.

About Irritable Bowel Syndrome with Diarrhea (IBS-D)
Irritable bowel syndrome with diarrhea (IBS-D) is a chronic gastrointestinal disorder characterized by recurrent abdominal pain associated with frequent, loose or watery stools. An estimated 4.5 million adults in the United States are affected by IBS-D with a high rate of recurrence (derived from Rome IV IBS prevalence of 6.1% and an IBS-D share of 28.1%; Almario et al., Gastroenterology 2023). There are limited treatment options that adequately address both pain and bowel symptoms.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; uncertainty related to the timing and amounts expected to be realized from future milestone, contingent value right, royalty or similar future revenue streams, if at all; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of product candidates under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com  

LONG BEACH, Calif. and TORONTO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (NYSE: GLAS), one of the fastest-growing cannabis companies in the U.S., today announced that it will report financial results for the third quarter ended September 30, 2026, on Monday, November 16, 2026, after market close. The Company will host a conference call to discuss the results at 5:00 p.m. Eastern Time the same day.

Participants can find the live webcast here or on the Glass House Brands website. The webcast will be archived for approximately 30 days. Participants interested in dialing in can call 1.800.715.9871 or 1.646.307.1963 and type in the Conference ID 1740059 when the line is picked up. A replay of the call will be available here. The Company also posts all historical earnings call webcast audio files, call transcripts, financial statements, and management discussions and analyses here.

About Glass House Brands Inc.
Glass House is one of the fastest-growing cannabis companies in the U.S., with a dedicated focus on the California market and building leading, lasting brands to serve consumers across all segments. Whether it be through its portfolio of brands, which includes Glass House Farms, PLUS Products, Allswell and Mama Sue Wellness, Glass House is committed to realizing its vision of excellence: outstanding cannabis products, produced sustainably, for the benefit of all. For more information and company updates, visit www.glasshousebrands.com/ and https://ir.glasshousebrands.com/contact/email-alerts/.

Forward-Looking Statements
This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or Glass House’s future performance or financial results. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward- looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements regarding the Company’s financial outlook or operational plans and statements related to future market conditions. All forward-looking statements, including those herein, are qualified by this cautionary statement. Although Glass House believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. Accordingly, readers should not place undue reliance on forward-looking statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information, including those risks disclosed in the Glass House’s Annual Information Form available on SEDAR+ at www.sedarplus.ca and in Glass House’s Form 40-F available on EDGAR at www.sec.gov. For more information on Glass House, investors are encouraged to review Glass House’s public filings on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. The forward-looking statements and financial outlooks contained in this news release speak only as of the date of this news release or as of the date or dates specified in such statements. Glass House disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

For further information, please contact:

Investor Relations Contact:
KCSA Strategic Communications
Phil Carlson
T: 212-896-1233
E: GlassHouseIR@KCSA.com

EL MONTE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Erica Wei, its Chief Financial Officer, will participate in three upcoming investor conferences in November.

RBC Capital Markets Global Technology, Internet, Media & Telecommunications Conference

• Fireside chat at 1:20pm ET on Tuesday, November 17, 2026 in New York City.
• One-one-one investor meetings throughout the day.

15^th Annual ROTH Technology Conference

• One-one-one investor meetings throughout the day on Wednesday, November 18, 2026 in New York City.

2026 Furey Research Hidden Gems Conference

• Virtual presentation at 1:00pm ET on Tuesday, November 24, 2026.
• One-one-one investor meetings throughout the day.

Investors wishing to schedule a meeting with GigaCloud at these conferences should contact your representative at RBC Capital Markets, ROTH, and Furey Research Partners, respectively, or PondelWilkinson at tkehrli@pondel.com.

About GigaCloud Technology Inc

GigaCloud Technology Inc is a pioneer of global end-to-end B2B technology solutions for large parcel merchandise. The Company’s B2B ecommerce platform, which it refers to as the “GigaCloud Marketplace,” integrates everything from discovery and payments to logistics tools into one easy-to-use platform. The Company’s global marketplace seamlessly connects manufacturers, primarily in Asia, with resellers, primarily in the U.S., Asia and Europe, to execute cross-border transactions with confidence, speed and efficiency. The Company offers a truly comprehensive solution that transports products from the manufacturer’s warehouse to the end customer’s doorstep, all at one fixed price. The Company first launched its marketplace in January 2019 by focusing on the global furniture market and has since expanded into additional categories such as home appliances and fitness equipment. For more information, please visit the Company’s website: https://investors.gigacloudtech.com/.

For investor and media inquiries, please contact:

GigaCloud Technology Inc
Investor Relations – ir@gigacloudtech.com

PondelWilkinson Inc.
Todd Kehrli (Investors) – tkehrli@pondel.com
Laurie Berman (Investors) – lberman@pondel.com
George Medici (Media) – gmedici@pondel.com

RevPAS Increases 16% Driven by Utilization Improvement

Contract Volumes Up 13% and Transient Volumes Up 11%

Conference Call to be held at 4:30 PM Eastern Time Today

CINCINNATI, Nov. 10, 2026 (GLOBE NEWSWIRE) — Mobile Infrastructure Corporation (Nasdaq: BEEP), (“Mobile”, “Mobile Infrastructure” or the “Company”), the nation’s only publicly traded owner of parking infrastructure, today reported results for the three and nine months ended September 30, 2026.

“We are pleased with our third quarter results, marking Mobile’s strongest operating quarter of 2026, building strong momentum heading into 2027, and achieving our highest utilization and RevPAS to date,” said Stephanie Hogue, Chief Executive Officer. “At the start of the year, we discussed our strategy of building utilization first, establishing a larger and more durable base of recurring and transient demand, and following this with improved, sustainable pricing as utilization improves. Our results in the third quarter evidence strong execution as our strategy translates into earnings improvement. Same-Location Revenue grew 12.8% and Same-Location NOI increased 18.4%, marking our third consecutive quarter of Same-Location NOI growth and a clear acceleration from the first half of the year.

“In the third quarter, our growth was principally volume-driven. Utilization rose approximately 13 percentage points year-over-year and RevPAS increased approximately 16%, reaching its highest level since we began tracking the measure in 2023. Monthly parking is the foundation of that progress. Baseline contract volumes grew approximately 13%, supported by residential demand, commercial relationships, and targeted business development, with Cincinnati, Fort Worth, and Detroit among the leading contributors. Recurring contracts give us greater revenue visibility and a more stable base from which to optimize transient inventory, which supports improved pricing over time. Transient demand benefited from an active summer event calendar and a growing share of third-party reservations, with notable strength in Chicago, Cincinnati, and Nashville. We have deliberately prioritized utilization and customer relationships, and we expect to achieve pricing power as more of the portfolio reaches stabilized utilization.

“We continue to execute our disciplined capital allocation strategy. To date, we have generated approximately $33 million of proceeds under our three-year $100 million asset rotation program, at a weighted-average capitalization rate of approximately 2%. These private-market valuations reinforce the underlying value of our portfolio and the disconnect from our current share price. Our priorities remain clear: maximize the performance of our existing assets, improve portfolio quality and strengthen the balance sheet, all to build long-term shareholder value,” Ms. Hogue concluded.

Third Quarter 2026 Highlights

• Total revenue was $9.6 million, up 5.5%, as compared to $9.1 million in the prior-year period and $8.9 million in Q2.
• Same-Location Revenue was $9.6 million, up 12.8%, as compared to $8.5 million in the prior-year period.
• Net loss was $2.6 million as compared to $6.4 million in the prior-year period and $3.2 million in Q2.
• NOI* was $6.3 million as compared to $5.5 million in the prior-year period, an increase of 13.6% year-over-year.
• Same-Location NOI* was $6.3 million as compared to $5.3 million in the prior-year period, an increase of 18.4% year-over-year.
• Adjusted EBITDA* was $4.8 million as compared to $3.9 million in the prior-year period, an increase of 23.2% year-over-year.
• Contract parking volumes grew approximately 13% year-over-year, supported by continued strength in residential and return-to-office momentum.

* Explanations of these non-GAAP financial measures and reconciliation to the most comparable GAAP financial measures are presented later in this press release.

Q3 2026 Financial Results

Total revenue of $9.6 million increased by 5.5% from $9.1 million in the prior-year quarter. Same-Location Revenue was $9.6 million, an increase of 12.8% compared to $8.5 million in the third quarter of 2025. Revenue increases are primarily due to growth in managed property revenue driven by contract and transient volume increases.

Total property taxes and operating expenses were $3.3 million, as compared to $3.6 million during the third quarter of 2025.

General and administrative expenses were $2.3 million, which included $0.8 million of non-cash compensation, compared to $2.4 million during the third quarter of 2025, which included $0.8 million of non-cash compensation.

Interest expense was $4.8 million compared to $4.6 million in the third quarter of 2025.

Net loss was $2.6 million, an improvement from $6.4 million in the prior-year period, which included a non-cash $2.5 million impairment of real estate.

Same-Location Net Operating Income (“Same-Location NOI”), defined by the Company as total revenues less property taxes and operating expenses for the 35 properties owned during both reported periods, was $6.3 million, up 18.4% from $5.3 million in the prior-year period. Growth was driven primarily by contract and transient volume increases together with disciplined operating expense control. Adjusted EBITDA was $4.8 million compared to $3.9 million in the prior-year period.

Revenue Per Available Stall (“RevPAS”) was $245.83, compared to $211.53 in the third quarter of 2025 and $224.96 in the second quarter of 2026. Trailing twelve-month RevPAS was $211.22, compared to $202.53 a year earlier. Portfolio utilization was up approximately 13 percentage points year-over-year in the third quarter and approximately 8 percentage points on a trailing twelve-month basis, reflecting continued contract growth and the reopening of several demand-driving venues across the portfolio driving transient volumes.

Balance Sheet, Cash Flow, and Liquidity

At September 30, 2026, the Company had $10.6 million in cash, cash equivalents and restricted cash, compared to $15.3 million at December 31, 2025. As of September 30, 2026, total debt outstanding, net, including outstanding borrowings under the Line of Credit and notes payable, was $198.3 million, down from $207.7 million at yearend 2025.

Full Year 2026 Guidance**

The Company is reiterating its full year 2026 guidance range as initially provided with fourth quarter and full year 2025 results. Based on our results to date, for full year 2026, the Company expects revenue to be at the low end of the range of $35 million to $38 million.

The Company expects NOI to range from $21.5 million to $23.0 million, representing year-over-year growth of 7% at the midpoint, and 10% growth on a same-location basis. The Company expects adjusted EBITDA to range from $15.0 million to $16.5 million, representing year-over-year growth of 10% at the midpoint, and 13% growth on a same-location basis.

This guidance is supported by expectations for continued contract volume growth, the reopening and enhancement of several venues, and the positive impact from technology optimization across the Company’s core portfolio on pricing and utilization. The guidance does not reflect any potential future asset sales or acquisitions from the asset rotation plan.

**The Company does not provide a reconciliation for non-GAAP estimates on a forward-looking basis, where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items and the information is not available without unreasonable effort.

Third Quarter 2026 Conference Call and Webcast Information

Mobile will hold a conference call to discuss its third quarter 2026 results on November 10, 2026, at 4:30 p.m. ET.

Participants who wish to access the live conference call may do so by registering here. Upon registration, a dial-in and unique PIN will be provided to join the call.

A live, listen-only webcast of the conference call may be accessed from the Investor Relations section of the Company’s website, or by registering here.

For those who are unable to listen to the live broadcast, a replay of the webcast will be available in the “News & Events” section of the Investor Relations website under “IR Calendar” for one year.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this press release that are not historical facts (including any statements concerning our net operating income and revenue projections, our assessment of various trends impacting our economic performance, the effects of implementation of strategic model changes, other plans and objectives of management for future operations or economic performance, or assumptions or forecasts related thereto) are forward-looking statements. Forward-looking statements are typically identified by the use of terms such as “may,” “should,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “potential” or the negative of such terms and other comparable terminology.

The forward-looking statements included herein are based upon the Company’s current expectations, plans, estimates, assumptions and beliefs, which involve numerous risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, the actual results and performance could differ materially from those set forth in the forward-looking statements. Factors which could have a material adverse effect on operations and future prospects are discussed in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission from time to time.

All forward-looking statements are made as of the date of this press release. Except as otherwise required by the federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements.

About Mobile Infrastructure Corporation

Mobile Infrastructure Corporation is a Maryland corporation. The Company owns a diversified portfolio of parking assets throughout the United States. As of September 30, 2026, the Company owned 35 parking facilities in 18 separate markets throughout the United States, with a total of 13,200 parking spaces and approximately 4.6 million square feet. The Company also owns approximately 0.1 million square feet of retail/commercial space adjacent to its parking facilities. Learn more at www.mobileit.com.

Mobile Contact
David Gold | Lynn Morgen
beepir@advisiry.com | (212) 750-5800

MOBILE INFRASTRUCTURE CORPORATION CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts)
		As of September 30, 2026				As of December 31, 2025
		(unaudited)
ASSETS
Investments in real estate
Land and improvements		$	142,584			$	150,566
Buildings and improvements			236,590				244,627
Construction in progress			1,060				87
Intangible assets			5,717				5,717
			385,951				400,997
Accumulated depreciation and amortization			(44,136	)			(38,860	)
Total investments in real estate, net			341,815				362,137
Cash and cash equivalents			4,879				8,349
Cash – restricted			5,717				6,935
Accounts receivable, net			3,181				3,985
Other assets			1,462				1,058
Total assets		$	357,054			$	382,464
LIABILITIES AND EQUITY
Liabilities
Notes payable, net		$	175,395			$	181,771
Line of credit			22,927				25,895
Accounts payable and accrued expenses			14,037				15,196
Accrued preferred distributions and redemptions			81				67
Due to related parties			490				490
Total liabilities			212,930				223,419
Equity
Mobile Infrastructure Corporation Stockholders’ Equity
Preferred stock Series A, $0.0001 par value, 50,000 shares authorized, 576 and 1,296 shares issued and outstanding, with a stated liquidation value of $576,000 and $1,296,000 as of September 30, 2026 and December 31, 2025, respectively			—				—
Preferred stock Series 1, $0.0001 par value, 97,000 shares authorized, 12,590 and 13,315 shares issued and outstanding, with a stated liquidation value of $12,590,000 and $13,315,000 as of September 30, 2026 and December 31, 2025, respectively			—				—
Preferred stock Series 2, $0.0001 par value, 60,000 shares authorized, 46,000 issued and converted (stated liquidation value of zero as of September 30, 2026 and December 31, 2025)			—				—
Warrants issued and outstanding – zero and 2,553,192 warrants as of September 30, 2026 and December 31, 2025, respectively			—				3,319
Common stock, $0.0001 par value, 500,000,000 shares authorized, 39,378,079 and 39,662,049 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively			2				2
Additional paid-in capital			302,872				299,446
Accumulated deficit			(173,833	)			(161,496	)
Total Mobile Infrastructure Corporation Stockholders’ Equity			129,041				141,271
Non-controlling interest			15,083				17,774
Total equity			144,124				159,045
Total liabilities and equity		$	357,054			$	382,464

MOBILE INFRASTRUCTURE CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts, unaudited)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Revenues
Managed property revenue		$	8,544			$	7,673			$	22,927			$	21,659
Base rental income			1,013				1,279				3,113				4,185
Percentage rental income			27				134				369				469
Total revenues			9,584				9,086				26,409				26,313
Operating expenses
Property taxes			1,688				1,761				4,646				5,412
Property operating expense			1,642				1,820				5,051				5,497
Depreciation and amortization			1,762				2,874				5,365				7,822
General and administrative			2,250				2,438				7,256				7,230
Impairment			—				2,545				—				2,545
Total expenses			7,342				11,438				22,318				28,506
Other
Interest expense, net			(4,781	)			(4,568	)			(14,634	)			(13,908	)
Loss on extinguishment of debt			—				—				(2,044	)			—
Loss on sale of real estate			—				—				(1,115	)			—
Other income (expense), net			(11	)			34				125				(15	)
Change in fair value of Earn-Out liability			—				458				—				693
Total other expense			(4,792	)			(4,076	)			(17,668	)			(13,230	)
Net loss			(2,550	)			(6,428	)			(13,577	)			(15,423	)
Net loss attributable to non-controlling interest			(221	)			(625	)			(1,240	)			(1,480	)
Net loss attributable to Mobile Infrastructure Corporation’s stockholders		$	(2,329	)		$	(5,803	)		$	(12,337	)		$	(13,943	)
Preferred stock distributions declared – Series A			(13	)			(26	)			(49	)			(81	)
Preferred stock distributions declared – Series 1			(175	)			(209	)			(537	)			(671	)
Net loss attributable to Mobile Infrastructure Corporation’s common stockholders		$	(2,517	)		$	(6,038	)		$	(12,923	)		$	(14,695	)
Basic and diluted loss per weighted average common share:
Net loss per share attributable to Mobile Infrastructure Corporation’s common stockholders – basic and diluted		$	(0.06	)		$	(0.15	)		$	(0.33	)		$	(0.36	)
Weighted average common shares outstanding, basic and diluted			39,355,655				40,737,762				39,350,880				40,641,426

Discussion and Reconciliation of Non-GAAP Measures

Same-Location Net Operating Income

Net Operating Income (“NOI”) is presented as a supplemental measure of our performance. For the three and nine months ended September 30, 2026 and 2025, Same-Location NOI represents the NOI for the 35 properties that were owned for both calendar year periods being compared. The Company believes that NOI provides useful information to investors regarding our results of operations, as it highlights operating trends such as pricing and demand for our portfolio at the property level as opposed to the corporate level. NOI is calculated as total revenues less property operating expenses and property taxes. The Company uses NOI internally in evaluating property performance, measuring property operating trends, and valuing properties in our portfolio. Other real estate companies may use different methodologies for calculating NOI, and accordingly, the Company’s NOI may not be comparable to other real estate companies. NOI should not be viewed as an alternative measure of financial performance as it does not reflect the impact of general and administrative expenses, depreciation and amortization, interest expense, other income and expenses, or the level of capital expenditures necessary to maintain the operating performance of the Company’s properties that could materially impact results from operations.

Adjusted EBITDA

Adjusted Earnings Before Interest Expense, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) reflects net income (loss) excluding the impact of interest expense, depreciation and amortization, and the provision for income taxes, for all periods presented. Adjusted EBITDA also excludes certain recurring and non-recurring items including, but not limited to, stock-based compensation expense, non-cash changes in fair value of the Earn-Out Liability, gains or losses from disposition of real estate assets, impairment write-downs of depreciable property, and Other Income, Net. Adjusted EBITDA should be considered along with, but not as an alternative to, net income (loss), cash flow from operations or any other operating GAAP measure.

Same-Location Net Operating Income and Reconciliation to Net Loss

		For the Three Months Ended September 30,										For the Nine Months Ended September 30,
		2026				2025			%			2026				2025			%
Revenues
Managed property revenue		$	8,544			$	7,255					$	22,765			$	20,459
Base rental income			1,013				1,105						3,030				3,635
Percentage rental income			27				135						369				469
Total revenues			9,584				8,495		12.8	%			26,164				24,563		6.5	%
Operating expenses
Property taxes			1,688				1,670						4,696				5,093
Property operating expense			1,642				1,541						4,935				4,697
Same-Location Net Operating Income		$	6,254			$	5,284		18.4	%		$	16,533			$	14,773		11.9	%
Reconciliation
Net loss		$	(2,550	)		$	(6,428	)				$	(13,577	)		$	(15,423	)
Loss on extinguishment of debt			—				—						2,044				—
Loss on sale of real estate			—				—						1,115				—
Other (income) expense, net			11				(34	)					(125	)			15
Change in fair value of Earn-Out liability			—				(458	)					—				(693	)
Interest expense, net			4,781				4,568						14,634				13,908
Depreciation and amortization			1,762				2,874						5,365				7,822
General and administrative			2,250				2,438						7,256				7,230
Impairment			—				2,545						—				2,545
Net Operating Income		$	6,254			$	5,505					$	16,712			$	15,404
Less: 2025 and 2026 Disposed Assets			—				(221	)					(179	)			(631	)
Same-Location Net Operating Income		$	6,254			$	5,284					$	16,533			$	14,773

Adjusted EBITDA Reconciliation

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2026				2025				2026				2025
Reconciliation of Net Loss to Adjusted EBITDA Attributable to the Company
Net loss		$	(2,550	)		$	(6,428	)		$	(13,577	)		$	(15,423	)
Interest expense, net			4,781				4,568				14,634				13,908
Depreciation and amortization			1,762				2,874				5,365				7,822
Impairment			—				2,545				—				2,545
Change in fair value of Earn-Out liability			—				(458	)			—				(693	)
Other expense, net			11				(34	)			(125	)			15
Loss on extinguishment of debt			—				—				2,044				—
Loss on sale of real estate			—				—				1,115				—
Equity based compensation			762				801				2,358				2,289
Adjusted EBITDA Attributable to the Company		$	4,766			$	3,868			$	11,814			$	10,463

RevPAS

Revenue Per Available Stall (“RevPAS”) is used to evaluate parking operations and performance. RevPAS is defined as average monthly Parking Revenue (Parking Revenue less related Sales Tax and Credit Card Fees) divided by the parking stalls in the locations that were owned and under management agreement for the periods presented. Parking Revenue does not include Billboard or Commercial Rent, or revenue from locations that are under Lease Agreements. The Company believes RevPAS is a meaningful indicator of our performance because it measures the period-over-period change in revenues for comparable locations.

SAN JOSE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced its participation in the following financial conferences:

• BMO Technology and Innovation Leaders Conference on Nov. 12^th in New York. Astera Labs’ presentation is scheduled for 9:15 am ET.
• Raymond James 2026 TMT & Consumer Conference on Dec. 8^th in New York. Astera Labs’ presentation is scheduled for 9:20 am ET.
• Barclays 24th Annual Global Technology Conference on Dec. 9^th in San Francisco. Astera Labs’ presentation is scheduled for 2:00 pm PT.
• Needham Growth Conference on Jan. 12^th in New York. Astera Labs’ presentation time will be available on the investor relations website.

Webcasts of these sessions will be available on Astera Labs’ investor relations website at https://ir.asteralabs.com

About Astera Labs
Astera Labs (Nasdaq: ALAB) provides rack-scale AI infrastructure through purpose-built connectivity solutions. By collaborating with hyperscalers and ecosystem partners, Astera Labs enables organizations to unlock the full potential of modern AI. Astera Labs’ Intelligent Connectivity Platform integrates CXL^®, Ethernet, NVLink Fusion, PCIe^®, and UALink™ semiconductor-based technologies with the company’s COSMOS software suite to unify diverse components into cohesive, flexible systems that deliver end-to-end scale-up and scale-out connectivity. The company’s custom connectivity solutions business complements its standards-based portfolio, enabling customers to deploy tailored architectures to meet their unique infrastructure requirements. Discover more at www.asteralabs.com.

IR CONTACT: Leslie Green
leslie.green@asteralabs.com